IL128812A0 - Inhibition of 26S and 20S proteasome by indanones - Google Patents

Inhibition of 26S and 20S proteasome by indanones

Info

Publication number
IL128812A0
IL128812A0 IL12881297A IL12881297A IL128812A0 IL 128812 A0 IL128812 A0 IL 128812A0 IL 12881297 A IL12881297 A IL 12881297A IL 12881297 A IL12881297 A IL 12881297A IL 128812 A0 IL128812 A0 IL 128812A0
Authority
IL
Israel
Prior art keywords
indanones
proteasome
inhibition
mammals
cell proliferation
Prior art date
Application number
IL12881297A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of IL128812A0 publication Critical patent/IL128812A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
IL12881297A 1996-09-24 1997-09-23 Inhibition of 26S and 20S proteasome by indanones IL128812A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/719,042 US5834487A (en) 1996-09-24 1996-09-24 Inhibition of 26S and 20S proteasome by indanones
PCT/US1997/017013 WO1998013061A1 (en) 1996-09-24 1997-09-23 Inhibition of 26s and 20s proteasome by indanones

Publications (1)

Publication Number Publication Date
IL128812A0 true IL128812A0 (en) 2000-01-31

Family

ID=24888555

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12881297A IL128812A0 (en) 1996-09-24 1997-09-23 Inhibition of 26S and 20S proteasome by indanones

Country Status (23)

Country Link
US (2) US5834487A (de)
EP (1) EP0956031B1 (de)
JP (1) JP3347332B2 (de)
KR (1) KR100363067B1 (de)
CN (1) CN1220520C (de)
AT (1) ATE297748T1 (de)
AU (1) AU710438B2 (de)
BR (1) BR9711415A (de)
CA (1) CA2266884C (de)
CZ (1) CZ299837B6 (de)
DE (1) DE69733573T2 (de)
ES (1) ES2241057T3 (de)
GE (1) GEP20012512B (de)
HK (1) HK1020883A1 (de)
HU (1) HUP9904693A3 (de)
IL (1) IL128812A0 (de)
NO (1) NO323627B1 (de)
NZ (1) NZ334377A (de)
PL (1) PL189262B1 (de)
RU (1) RU2195310C2 (de)
TR (1) TR199900656T2 (de)
UA (1) UA57035C2 (de)
WO (1) WO1998013061A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
CN1339970A (zh) * 1999-02-10 2002-03-13 鹤尾隆 抗癌药物增强剂
EP1053750A1 (de) * 1999-04-22 2000-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gebrauch von Proteasom-Inhibitor zur Induktion von programmiertem Zelltod (Apoptose)
US20040116329A1 (en) * 2002-01-29 2004-06-17 Epstein Stephen E. Inhibition of proteasomes to prevent restenosis
WO2003070229A2 (de) * 2002-02-22 2003-08-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von proteinaseinhibitoren zur behandlung von autoimmunerkrankungen
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
JP5108509B2 (ja) * 2004-05-10 2012-12-26 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物
EP1637529A1 (de) * 2004-09-20 2006-03-22 4Sc Ag Neue Piperidin-4-yl-Thiazol-Carboxamid-Analog als Inhibitoren für die Vermehrung von T-Zellen und ihre Verwendung
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7319152B2 (en) 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
US7414142B2 (en) 2005-09-19 2008-08-19 Wyeth 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EP2730579A1 (de) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronatesterverbindungen und pharmazeutische Zusammensetzungen davon
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CN109180780B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
KR102481856B1 (ko) 2014-05-20 2022-12-26 밀레니엄 파머슈티컬스 인코퍼레이티드 일차 암 치료법 후 사용하기 위한 붕소-함유 프로테아좀 저해제
CN104370795B (zh) * 2014-10-15 2016-09-28 复旦大学 一种双靶向卵巢癌细胞微管蛋白及其周围血管的茚酮化合物及其制备方法与应用
CN104557559B (zh) * 2015-01-14 2016-08-17 成都中医药大学 茚满二酮手性环己烷螺环化合物及其制备方法与用途
CN108976145B (zh) * 2017-05-31 2020-12-01 首都医科大学 氨基正己酰氨基甲环酰氨基正己酰极性氨基酸，其合成，活性和应用
CN111467331B (zh) * 2020-05-19 2021-01-26 北京大学 1-茚酮在制备治疗或预防常染色体显性遗传多囊肾病药物的应用
US11452708B2 (en) * 2021-02-08 2022-09-27 King Abdulaziz University Discovery of potent [alpha]-glucosidase inhibitors from Heterophragma adenophyllum

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021413B1 (en) * 1988-08-24 1994-12-13 Sankyo Co Analgesic thiomorpholins, their preparation, and pharmaceutical compositions containing them
CA2086433C (en) * 1990-07-12 2000-01-25 Yuhpyng L. Chen Indano pyrrolidine carbamates
CA2109515A1 (en) * 1991-05-29 1992-11-30 Robert L. Dow Dihydroxyindanone tyrosine kinase inhibitors
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity

Also Published As

Publication number Publication date
EP0956031B1 (de) 2005-06-15
JP3347332B2 (ja) 2002-11-20
NO991406L (no) 1999-05-25
JP2000509406A (ja) 2000-07-25
UA57035C2 (uk) 2003-06-16
CA2266884C (en) 2005-08-23
GEP20012512B (en) 2001-08-27
RU2195310C2 (ru) 2002-12-27
PL189262B1 (pl) 2005-07-29
TR199900656T2 (xx) 1999-08-23
HUP9904693A3 (en) 2000-07-28
AU4495997A (en) 1998-04-17
US5834487A (en) 1998-11-10
BR9711415A (pt) 2000-01-18
KR100363067B1 (ko) 2002-12-05
KR20000048577A (ko) 2000-07-25
AU710438B2 (en) 1999-09-23
CN1220520C (zh) 2005-09-28
DE69733573D1 (de) 2005-07-21
NO991406D0 (no) 1999-03-23
NO323627B1 (no) 2007-06-18
ATE297748T1 (de) 2005-07-15
WO1998013061A1 (en) 1998-04-02
US6117887A (en) 2000-09-12
HUP9904693A2 (hu) 2000-06-28
HK1020883A1 (en) 2000-05-26
CN1231612A (zh) 1999-10-13
CZ95599A3 (cs) 1999-08-11
CZ299837B6 (cs) 2008-12-10
DE69733573T2 (de) 2006-05-04
ES2241057T3 (es) 2005-10-16
NZ334377A (en) 2000-11-24
PL332383A1 (en) 1999-09-13
CA2266884A1 (en) 1998-04-02
EP0956031A1 (de) 1999-11-17

Similar Documents

Publication Publication Date Title
IL128812A0 (en) Inhibition of 26S and 20S proteasome by indanones
BG103193A (en) Cellular adhesion inhibitors
BRPI9915679B8 (pt) composições e métodos para aumentar a mineralização óssea
EP0960124A4 (de) Serin-ersetzte mutanten des bcl-xl/bcl-2 assoziierten zelltodregulators
MX9703564A (es) Inhibidores de proteasa multicatalitica.
AU688952B2 (en) Thrombin inhibitors
MX9606546A (es) Compuestos inhibidores de la enzima conversiva de interleukina-1 beta.
AU2551997A (en) Compositions and processes for photogeneration of acid
BG104719A (en) Glucocorticoid-selective anti-inflammatory agents
ZA972000B (en) Inhibition of proliferation of cells.
EP0988044A4 (de) Pflanzenextrakte aus centipedia
ZA986673B (en) Use of a combination of an inhibitor of converting enzyme and a diuretic for treating microcirculatory disorders
BG103286A (en) Compositions and methods for ore dressing
AU3769097A (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
MY122278A (en) 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
EP0800649A4 (de) Hemmung der gliazellen-proliferation
EP0830130A4 (de) Tnf-alpha konvertierendes enzym
CA2284278A1 (en) Histone containing composition to treat rheumatoid arthritis
AU4499897A (en) Isolation and use of motoneuronotrophic factors
EP0724597A4 (de) Ks-laminin und methoden zur verwendung
ATE259222T1 (de) Substituierte diphenylindanone, -indane und - indolverbindungen und deren analogue zur verwendung in der prophylaxe und behandlung von krankheiten die sich durch anormale zellproliferation auszeichnen
ATE213644T1 (de) Kombinationstherapie für die behandlung von arthritis erkrankungen
MX9709783A (es) Inmortalizacion y desinmortalizacion de celulas.
KR200160702Y1 (en) Shielding plate for prevention of static electricity
UA13311A (uk) Склад для іhгібуваhhя hітрифікації азотhих добрив

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees